Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
PFS Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 11.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange ...
Pfizer (PFE) reported fourth quarter and full-year 2024 earnings results Tuesday, narrowly beating Wall Street expectations ...
Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...